ACUD-1 is under clinical development by Accuitis and currently in Phase II for Rosacea. According to GlobalData, Phase II drugs for Rosacea have a 38% phase transition success rate (PTSR) indication ...
Deucravacitinib is under clinical development by Bristol-Myers Squibb and currently in Phase II for Rosacea. According to GlobalData, Phase II drugs for Rosacea have a 38% phase transition success ...
INR:0494. is today match Novartis Piqray for PIK3CA mutation HR+/HER2- breast cancer: significantly prolonged survival The National Medical Insurance Bureau has re ...